The FDA approves wireless pressure-modulating goggles for home glaucoma treatment; Bausch + Lomb launches a new PreserVision AREDS eye vitamin formation; & an Executive Strategic Advisor discusses the regulation environment for communication in eye care: ow.ly/n6Tb50Z2pLT

CHMP backed EU marketing authorization for Fovlussea, a ranibizumab biosimilar, across five retinal disease indications, pending European Commission decision. ow.ly/lW4F5100Wjn

Siloton secured an £8.4 million Innovate UK contract to accelerate development and clinical evaluation of its handheld OCT system, GiraffeOCT. ow.ly/3ZsA5100Whz

FDA cleared Opus Genetics’ IND for OPGx-RDH12, advancing clinical development of its RDH12 gene therapy for Leber congenital amaurosis. Phase 1/2 is planned for Q4 2026. ow.ly/FwEU5100tj6

A large US registry study found 12.2% of glaucoma patients underwent a procedure during 18 to 36 months, and 56.3% had a care lapse over 12 months. ow.ly/U3yC5100tis

Zeiss Medical Technology announced the commercial availability of its CT Lucia 621P monofocal IOL in Japan, expanding its cataract surgery portfolio. ow.ly/XyW05100the

Perfect Corp. added a generative AI glasses removal feature to its virtual eyewear try-on tool, letting users keep prescription glasses on during try-on. ow.ly/qngh5100teC

Nanoscope Therapeutics reported preclinical data showing OCT-guided nonviral gene delivery produced sustained visual responses in mouse models of retinal degeneration. ow.ly/e2kT5100taz

EyewireTV AAO Coverage: Topcon Healthcare globally launches Oku Digital Health, an AI-powered company using routine eye care data to support earlier disease detection, clinical referrals & pharma research. Ali Tafreshi, CEO of both companies, explains. ow.ly/swwK50ZYU2U

Oculis reported phase 2 biomarker data from ACUITY showing Privosegtor reduced blood markers of neuroaxonal injury and glial activation vs placebo in acute optic neuritis. ow.ly/989j5100tkg

Brepocitinib met primary endpoints in two Phase 3 trials in noninfectious uveitis. Priovant also reported benefits in steroid-free quiescence, leakage, edema and visual functioning. ow.ly/1ezl51002wM

Alcon acquired Neurotech Pharmaceuticals for $550 million, adding Encelto, the first FDA-approved treatment for adults with idiopathic MacTel type 2, to its retina portfolio. ow.ly/KIY251002sC

Envision and VisionServe Alliance will hold its 2027 National Conference May 11-14 in Houston, with more than 400 expected attendees and 90 hours of programming. ow.ly/LQnW50ZZGxT

EyewireTV AAO Coverage: Rayner announces FDA approval and US availability of its RayOne Galaxy and RayOne Galaxy Toric IOLs, bringing its spiral optic platform to US cataract surgeons. Sam van Roon, Associate Vice President, Marketing, Rayner, explains. ow.ly/6Txy50ZYTZv

This week on EyewireTV: FDA approves Genentech's Enspryng as the first at-home treatment for thyroid eye disease, plus part 2 of our #AAO2026 coverage with Leica, Sight Sciences, Balance Ophthalmics, VEO Ophthalmics, Lumenis and VirtuaLens. Watch now: ow.ly/WLG550ZZOKX

RxSight named Taryn Conway chief commercial officer and Frank Shields EVP of sales and commercial strategy as it works to expand adoption of Light Adjustable Lens technology. ow.ly/YfvS51002us

SpyGlass Pharma reported positive 4-year first-in-human results for its Bimatoprost Drug Pad-IOL System in patients with mild-to-moderate open angle glaucoma or ocular hypertension. ow.ly/6lxX50ZZGzI

FDA approved Opus Genetics’ supplemental application for Ryzumvi, expanding its U.S. indications to include presbyopia in adults. The approval was supported by VEGA-2 and VEGA-3. ow.ly/m6Nh50ZZGvs

EyewireTV AAO Coverage: Heidelberg debuts the Heidelberg Opera, a fully digital ophthalmic surgical microscope with large-format displays, high color, contrast & resolution, and image enhancement. Heidelberg Engineering USA President Jeff Sieve explains. ow.ly/gisw50ZYTUW

EyePoint said the second pivotal phase 3 trial of Duravyu in wet AMD missed its primary endpoint, though it showed visual improvement and met key secondary endpoints. ow.ly/clTc50ZZGty

Oculis completed randomization in PREDICT-1, its Phase 2 trial of licaminlimab in dry eye disease. Topline results are expected around the end of 2026. ow.ly/lz9150ZZj26